The Therapeutic Effect of 1,8-Cineol on Pathogenic Bacteria Species Present in Chronic Rhinosinusitis

Matthias Schürmann1, Felix Oppel1, Martin Gottschalk2

  • 1Department of Otolaryngology, Head and Neck Surgery, Klinikum Bielefeld, Bielefeld, Germany.

Frontiers in Microbiology
|November 12, 2019
PubMed

Insights

1,8-Cineol effectively inhibits chronic rhinosinusitis (CRS) pathogens and their biofilm formation. This molecule targets key biofilm genes in Staphylococcus aureus, offering a promising new therapeutic avenue for CRS treatment.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Chronic rhinosinusitis (CRS) significantly impairs quality of life due to inflamed sinus mucosa.
  • Current CRS treatment lacks specific guidelines, leading to high healthcare costs and persistent symptoms.
  • Bacterial infections, microbiome shifts, and biofilm formation are key drivers of CRS progression, complicating antibiotic efficacy.

Purpose of the Study:

  • To characterize microbiome alterations in CRS patients.
  • To investigate the efficacy of 1,8-Cineol in inhibiting bacterial proliferation and biofilm formation in CRS pathogens.
  • To explore the molecular mechanisms underlying 1,8-Cineol's anti-biofilm activity and its effects on host immune response.

Main Methods:

  • MALDI-TOF MS used for microbiome profiling in CRS patients and healthy controls.
  • In vitro assays to measure bacterial proliferation and biofilm inhibition by 1,8-Cineol.
  • RT-qPCR to analyze gene expression related to biofilm formation (agrA, SarA, σB).
  • In vitro host models using respiratory epithelium and organotypic slices to assess biofilm inhibition and immune response.

Main Results:

  • CRS microbiomes showed a shift towards pathogens like Staphylococcus aureus, Escherichia coli, and Moraxella catarrhalis.
  • 1,8-Cineol demonstrated significant inhibition of bacterial proliferation and, notably, biofilm growth for these pathogens.
  • Staphylococcus aureus biofilm inhibition by 1,8-Cineol correlated with downregulation of key biofilm genes (agrA, SarA, σB).
  • 1,8-Cineol showed efficacy in inhibiting S. aureus biofilms on respiratory epithelium and modulated immune responses in organotypic slice models.

Conclusions:

  • 1,8-Cineol is a potent inhibitor of CRS-associated bacterial biofilms, targeting key regulatory genes.
  • The study identified specific pathogens in CRS and highlighted 1,8-Cineol's potential as a novel therapeutic agent.
  • Developed in vitro models offer a platform for testing 1,8-Cineol and other agents against various bacterial biofilms and host tissues.